Can-Fite BioPharma Ltd. (CANF) Form 424B3 — Oct 9, 2026
Can-Fite BioPharma filed a 424B3 prospectus registering the resale by selling shareholders of up to 6,589,796 ordinary shares (3,294,898 ADSs) issuable upon exercise of warrants issued in a March 2026 warrant repricing, in which the exercise price was cut to $2.50 per ADS. The company will receive no proceeds from shareholder sales, though it could receive approximately $8.31 million if all warrants are exercised for cash; new warrants carry a $5.00 exercise price and are exercisable until the two-year anniversary of the resale registration statement's effectiveness.
Key figures
- Offering Price
- 2.1
- Shares Offered
- 6,589,796 ordinary shares represented by 3,294,898 ADSs
- Shares Outstanding
- 6063093
- Ads ratio
- 1 ADS = 2 ordinary shares
- Prior ads ratio
- 1 ADS = 300 ordinary shares (one-for-twenty reverse ADS split, Jan 5, 2026)
- Registration expenses
- $44,000
- New warrant exercise price per ads
- $5.00
- Potential warrant exercise proceeds
- $8.31 million
- Total shareholders equity jun 30 2026
- $4.855 million
- Repriced warrant exercise price per ads
- $2.50
- Weighted avg warrant exercise price per ads
- $7.29
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.